Drugs / XKDCT080
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05875402 | Apr → Dec 2023 | colon carcinoma | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XKDCT080 | “The goal of this clinical trial is to assessing the safety and tolerability of XKDCT080 cells against recurrent or refractory solid tumors with GCC positivity.This experiment...” NCT05875402 ↗ |
| Modality | Cell therapy | “the experimental drug is a chimeric antigen receptor T cell preparation targeting GCC” NCT05875402 ↗ |
| Route | Intravenous | “after intravenous infusion into GCC-positive patients” NCT05875402 ↗ |